HC Wainwright & Co. Maintains Buy on Nuvectis Pharma, Raises Price Target to $39

Benzinga Newsdesk www.benzinga.com Positive 77.8%

Neg 0% Neu 0% Pos 77.8%

HC Wainwright & Co. analyst Joseph Pantginis maintains Nuvectis Pharma (NASDAQ:NVCT) with a Buy and raises the price target from $13 to $39.